ClinicalTrials.gg
CompletedNCT05247489Updated Feb 20, 2025Results posted

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

A Phase 2 interventional study of Ruxolitinib 1.5% cream and NB-UVB phototherapy in Vitiligo, sponsored by Incyte Corporation. Completed at 13 sites in 2 countries. Open to participants aged 12 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
12 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.

Enrollment
9th of 14
55 · median 90
Started
2022
the only one that year
Phase 2
5 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
9 of 14
Incyte Corporation

Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 7th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 12 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ruxolitinib in Vitiligo, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

03

Conditions studied

  • Vitiligo

Keywords

  • Non-segmental
  • Vitiligo
  • hypopigmentation
  • Pigment Disorders
  • Skin Diseases
  • JAK inhibitor
04

Who can participate

Ages eligible
12 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of nonsegmental vitiligo with depigmented area including all of the following:

    1. ≥ 0.5 F-VASI on the face
    2. ≥ 3.0 T-VASI (body areas not including the face)
    3. Total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.
  • Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.

Exclusion criteria

Exclusion Criteria:

  • No pigmented hair within any of the vitiligo areas on the face.
  • Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders.
  • Used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.
  • Previous adverse reaction to NB-UVB phototherapy that caused discontinuation of therapy.
  • Lack of response (little or no repigmentation) to prior NB-UVB phototherapy.
  • History of thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction).
  • Any other skin disease that, in the opinion of the investigator, would interfere with the study cream application or study assessments.
  • Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chicken pox) within 1 week before baseline.
  • Any serious illness or medical, physical, or psychiatric condition(s) that pose a significant risk to the participant; or interfere with interpretation of study data.
  • Recent use of topical or systemic medications (including biologics or JAK inhibitors), or laser or phototherapy to treat vitiligo. Note: Recent may be defined differently for different treatments.
  • Specific protocol-defined chemistry, hematology, and serological lab values.
  • Those who are pregnant, lactating or considering pregnancy during the period of study participation.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Group A: Ruxolitinib + Narrow-Band Ultraviolet B Phototherapy (NB-UVB)

    Participants will initially apply ruxolitinib 1.5%mg cream as a monotherapy. At week 12, those who have \< 25% improvement in total body Vitiligo Area Scoring Index (T-VASI25) will have NB-UVB phototherapy added to their ruxolitinib 1.5% cream BID regimen. NB-UVB will be given 3 times per week starting at Week 12 through Week 48 (36 weeks). For participants who receive combination therapy, NB-UVB machines will be supplied by the sponsor for at home use during the study.

    Drug: Ruxolitinib 1.5% cream · Device: NB-UVB phototherapy

  • Experimental
    Group B: Ruxolitinib Monotherapy

    Participants will apply ruxolitinib 1.5% cream BID as monotherapy. Participants who have ≥ T-VASI25 at Week 12 will continue on ruxolitinib 1.5% cream BID alone.

    Drug: Ruxolitinib 1.5% cream

Interventions

  • Ruxolitinib cream 1.5% applied twice a day (BID).

  • DeviceNB-UVB phototherapy

    NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit

    Also known as: Narrow-Band Ultraviolet B Phototherapy

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48

    T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of body surface area \[BSA\] estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Week 48

Secondary outcomes

  1. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

    Time frame: up to approximately 52 weeks

  2. Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Each Post-Baseline Visit

    An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; up to Week 48

  3. Percentage of Participants Achieving a ≥75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Each Post-Baseline Visit

    An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; up to Week 48

  4. Percentage of Participants Achieving a ≥90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Each Post-Baseline Visit

    An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; up to Week 48

  5. Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Each Post-Baseline Visit

    A T-VASI50 responder achieved ≥50% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; up to Week 48

  6. Percentage of Participants Achieving a ≥75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75) Score at Each Post-Baseline Visit

    A T-VASI75 responder achieved ≥75% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; up to Week 48

  7. Percentage of Participants Achieving a ≥90% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI90) Score at Each Post-Baseline Visit

    A T-VASI90 responder achieved ≥90% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; up to Week 48

  8. Change From Baseline in F-VASI at Each Post-Baseline Visit

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to Week 48

  9. Percentage Change From Baseline in F-VASI at Each Post-Baseline Visit

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

    Time frame: Baseline; up to Week 48

  10. Change From Baseline in T-VASI at Each Post-Baseline Visit

    T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value.

    Time frame: Baseline; up to Week 48

  11. Percentage Change From Baseline in T-VASI at Each Post-Baseline Visit

    T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; up to Week 48

  12. Change From Baseline in Facial Body Surface Area (F-BSA) at Each Post-Baseline Visit

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to Week 48

  13. Percentage Change From Baseline in F-BSA at Each Post-Baseline Visit

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

    Time frame: Baseline; up to Week 48

  14. Change From Baseline in Total Body Surface Area (T-BSA) at Each Post-Baseline Visit

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to Week 48

  15. Percentage Change From Baseline in T-BSA at Each Post-Baseline Visit

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; up to Week 48

  16. Plasma Concentration of Ruxolitinib at Weeks 4, 12, and 16

    The concentration of ruxolitinib in the plasma was assessed.

    Time frame: pre-application at Weeks 4, 12, and 16

07

Results

Posted Feb 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Started2035
Completed626
Not completed149
Withdrew: Lost to follow-up51
Withdrew: Withdrawal by subject67
Withdrew: Withdrawn by sponsor: noncompliance01
Withdrew: Left country10
Withdrew: Noncompliance with investigational product10
Withdrew: Withdrawn by sponsor: surgery to remove excess skin10

Outcome measures

PrimaryChange From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48

T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of body surface area \[BSA\] estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Total Body Vitiligo Area Scoring Index (T-VASI) at Week 48
scores on a scaleRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Baseline6.58 ± 2.1636.87 ± 2.103
Change from Baseline at Week 48-3.43 ± 1.219-3.46 ± 2.106
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

Time frame:
up to approximately 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)921
SecondaryPercentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Each Post-Baseline Visit

An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Each Post-Baseline Visit
percentage of participantsRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 46.3 (0.2 to 30.2)5.7 (0.7 to 19.2)
Week 821.4 (4.7 to 50.8)17.1 (6.6 to 33.6)
Week 1263.6 (30.8 to 89.1)31.4 (16.9 to 49.3)
Week 1685.7 (42.1 to 99.6)45.7 (28.8 to 63.4)
Week 24100.0 (59.0 to 100.0)76.5 (58.8 to 89.3)
Week 32100.0 (54.1 to 100.0)87.5 (71.0 to 96.5)
Week 40100.0 (54.1 to 100.0)92.9 (76.5 to 99.1)
Week 48100.0 (54.1 to 100.0)96.2 (80.4 to 99.9)
SecondaryPercentage of Participants Achieving a ≥75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Each Post-Baseline Visit

An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Each Post-Baseline Visit
percentage of participantsRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 46.3 (0.2 to 30.2)0.0 (0.0 to 10.0)
Week 87.1 (0.2 to 33.9)0.0 (0.0 to 10.0)
Week 1245.5 (16.7 to 76.6)14.3 (4.8 to 30.3)
Week 1657.1 (18.4 to 90.1)20.0 (8.4 to 36.9)
Week 2485.7 (42.1 to 99.6)47.1 (29.8 to 64.9)
Week 3283.3 (35.9 to 99.6)59.4 (40.6 to 76.3)
Week 40100.0 (54.1 to 100.0)71.4 (51.3 to 86.8)
Week 48100.0 (54.1 to 100.0)84.6 (65.1 to 95.6)
SecondaryPercentage of Participants Achieving a ≥90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Each Post-Baseline Visit

An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Each Post-Baseline Visit
percentage of participantsRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 40.0 (0.0 to 20.6)0.0 (0.0 to 10.0)
Week 80.0 (0.0 to 23.2)0.0 (0.0 to 10.0)
Week 129.1 (0.2 to 41.3)0.0 (0.0 to 10.0)
Week 1642.9 (9.9 to 81.6)2.9 (0.1 to 14.9)
Week 2442.9 (9.9 to 81.6)17.6 (6.8 to 34.5)
Week 3250.0 (11.8 to 88.2)34.4 (18.6 to 53.2)
Week 4050.0 (11.8 to 88.2)53.6 (33.9 to 72.5)
Week 4866.7 (22.3 to 95.7)53.8 (33.4 to 73.4)
SecondaryPercentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Each Post-Baseline Visit

A T-VASI50 responder achieved ≥50% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Each Post-Baseline Visit
percentage of participantsRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 40.0 (0.0 to 20.6)0.0 (0.0 to 10.0)
Week 80.0 (0.0 to 23.2)0.0 (0.0 to 10.0)
Week 1218.2 (2.3 to 51.8)0.0 (0.0 to 10.0)
Week 1642.9 (9.9 to 81.6)2.9 (0.1 to 14.9)
Week 2471.4 (29.0 to 96.3)23.5 (10.7 to 41.2)
Week 3266.7 (22.3 to 95.7)34.4 (18.6 to 53.2)
Week 4083.3 (35.9 to 99.6)46.4 (27.5 to 66.1)
Week 4883.3 (35.9 to 99.6)57.7 (36.9 to 76.6)
SecondaryPercentage of Participants Achieving a ≥75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75) Score at Each Post-Baseline Visit

A T-VASI75 responder achieved ≥75% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI75) Score at Each Post-Baseline Visit
percentage of participantsRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 40.0 (0.0 to 20.6)0.0 (0.0 to 10.0)
Week 80.0 (0.0 to 23.2)0.0 (0.0 to 10.0)
Week 120.0 (0.0 to 28.5)0.0 (0.0 to 10.0)
Week 160.0 (0.0 to 41.0)0.0 (0.0 to 10.0)
Week 2428.6 (3.7 to 71.0)5.9 (0.7 to 19.7)
Week 3250.0 (11.8 to 88.2)6.3 (0.8 to 20.8)
Week 4050.0 (11.8 to 88.2)7.1 (0.9 to 23.5)
Week 4850.0 (11.8 to 88.2)19.2 (6.6 to 39.4)
SecondaryPercentage of Participants Achieving a ≥90% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI90) Score at Each Post-Baseline Visit

A T-VASI90 responder achieved ≥90% improvement from Baseline in T-VASI, calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI90) Score at Each Post-Baseline Visit
percentage of participantsRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 40.0 (0.0 to 20.6)0.0 (0.0 to 10.0)
Week 80.0 (0.0 to 23.2)0.0 (0.0 to 10.0)
Week 120.0 (0.0 to 28.5)0.0 (0.0 to 10.0)
Week 160.0 (0.0 to 41.0)0.0 (0.0 to 10.0)
Week 2414.3 (0.4 to 57.9)2.9 (0.1 to 15.3)
Week 3216.7 (0.4 to 64.1)3.1 (0.1 to 16.2)
Week 4016.7 (0.4 to 64.1)7.1 (0.9 to 23.5)
Week 4816.7 (0.4 to 64.1)7.7 (0.9 to 25.1)
SecondaryChange From Baseline in F-VASI at Each Post-Baseline Visit

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in F-VASI at Each Post-Baseline Visit
scores on a scaleRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Baseline1.00 ± 0.4460.91 ± 0.522
Week 4-0.13 ± 0.234-0.05 ± 0.114
Week 8-0.26 ± 0.302-0.14 ± 0.204
Week 12-0.51 ± 0.382-0.32 ± 0.330
Week 16-0.68 ± 0.319-0.41 ± 0.428
Week 24-0.83 ± 0.276-0.60 ± 0.536
Week 32-0.87 ± 0.311-0.70 ± 0.514
Week 40-0.88 ± 0.326-0.79 ± 0.582
Week 48-0.88 ± 0.322-0.82 ± 0.603
SecondaryPercentage Change From Baseline in F-VASI at Each Post-Baseline Visit

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

Time frame:
Baseline; up to Week 48
Reported as:
Mean · percent change
Percentage Change From Baseline in F-VASI at Each Post-Baseline Visit
percent changeRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 4-11.69 ± 20.612-6.24 ± 12.472
Week 8-25.57 ± 24.957-14.62 ± 20.210
Week 12-54.62 ± 34.297-32.43 ± 26.031
Week 16-73.31 ± 27.030-40.64 ± 27.945
Week 24-87.02 ± 12.247-61.31 ± 28.613
Week 32-89.37 ± 11.661-72.69 ± 24.815
Week 40-90.44 ± 11.006-80.70 ± 20.478
Week 48-90.73 ± 11.002-85.55 ± 15.856
SecondaryChange From Baseline in T-VASI at Each Post-Baseline Visit

T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from BL was calculated as the post-BL value minus the BL value.

Time frame:
Baseline; up to Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in T-VASI at Each Post-Baseline Visit
scores on a scaleRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Baseline6.58 ± 2.1636.87 ± 2.103
Week 4-0.40 ± 0.711-0.06 ± 0.179
Week 8-0.85 ± 0.865-0.17 ± 0.480
Week 12-1.61 ± 1.320-0.52 ± 0.710
Week 16-2.47 ± 1.532-0.94 ± 0.949
Week 24-3.21 ± 1.686-1.73 ± 1.679
Week 32-3.03 ± 1.542-2.34 ± 1.746
Week 40-3.42 ± 1.235-2.97 ± 1.867
Week 48-3.43 ± 1.219-3.46 ± 2.106
SecondaryPercentage Change From Baseline in T-VASI at Each Post-Baseline Visit

T-VASI was calculated with contributions from 6 body sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each body site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; up to Week 48
Reported as:
Mean · percent change
Percentage Change From Baseline in T-VASI at Each Post-Baseline Visit
percent changeRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 4-6.12 ± 11.217-1.02 ± 3.063
Week 8-15.21 ± 15.360-2.79 ± 6.833
Week 12-29.76 ± 24.512-7.88 ± 9.796
Week 16-42.28 ± 23.530-14.82 ± 15.536
Week 24-57.31 ± 26.271-27.54 ± 26.386
Week 32-61.19 ± 28.399-35.51 ± 27.266
Week 40-69.63 ± 19.748-43.76 ± 27.441
Week 48-69.76 ± 18.519-50.39 ± 28.689
SecondaryChange From Baseline in Facial Body Surface Area (F-BSA) at Each Post-Baseline Visit

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to Week 48
Reported as:
Mean · percentage of facial surface area
Change From Baseline in Facial Body Surface Area (F-BSA) at Each Post-Baseline Visit
percentage of facial surface areaRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Baseline1.12 ± 0.5240.96 ± 0.615
Week 4-0.04 ± 0.126-0.02 ± 0.088
Week 8-0.08 ± 0.148-0.06 ± 0.194
Week 12-0.25 ± 0.246-0.17 ± 0.299
Week 16-0.40 ± 0.283-0.22 ± 0.378
Week 24-0.63 ± 0.150-0.34 ± 0.426
Week 32-0.70 ± 0.167-0.44 ± 0.457
Week 40-0.75 ± 0.207-0.58 ± 0.577
Week 48-0.77 ± 0.234-0.67 ± 0.716
SecondaryPercentage Change From Baseline in F-BSA at Each Post-Baseline Visit

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

Time frame:
Baseline; up to Week 48
Reported as:
Mean · percent change
Percentage Change From Baseline in F-BSA at Each Post-Baseline Visit
percent changeRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 4-4.02 ± 12.769-1.50 ± 4.345
Week 8-7.25 ± 13.838-4.37 ± 12.349
Week 12-24.12 ± 22.508-14.83 ± 19.575
Week 16-39.37 ± 35.289-19.34 ± 23.332
Week 24-65.36 ± 25.090-34.37 ± 30.969
Week 32-72.67 ± 20.378-45.42 ± 31.086
Week 40-77.02 ± 20.748-56.25 ± 31.498
Week 48-78.06 ± 20.018-60.51 ± 29.172
SecondaryChange From Baseline in Total Body Surface Area (T-BSA) at Each Post-Baseline Visit

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to Week 48
Reported as:
Mean · percentage of total body surface area
Change From Baseline in Total Body Surface Area (T-BSA) at Each Post-Baseline Visit
percentage of total body surface areaRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Baseline7.00 ± 2.3017.22 ± 2.118
Week 4-0.19 ± 0.701-0.02 ± 0.200
Week 8-0.48 ± 0.794-0.01 ± 0.430
Week 12-0.96 ± 0.952-0.17 ± 0.544
Week 16-1.43 ± 1.359-0.34 ± 0.659
Week 24-2.14 ± 1.462-0.80 ± 1.538
Week 32-2.13 ± 1.556-1.12 ± 1.689
Week 40-2.33 ± 1.617-1.50 ± 1.988
Week 48-2.37 ± 1.627-1.93 ± 2.312
SecondaryPercentage Change From Baseline in T-BSA at Each Post-Baseline Visit

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; up to Week 48
Reported as:
Mean · percent change
Percentage Change From Baseline in T-BSA at Each Post-Baseline Visit
percent changeRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 4-2.65 ± 10.057-0.36 ± 3.374
Week 8-7.71 ± 13.609-0.24 ± 6.006
Week 12-16.92 ± 17.590-2.60 ± 7.586
Week 16-23.09 ± 22.344-5.45 ± 9.946
Week 24-38.02 ± 23.485-12.50 ± 21.869
Week 32-42.86 ± 28.257-16.91 ± 23.758
Week 40-46.61 ± 29.639-21.92 ± 27.234
Week 48-47.03 ± 29.370-27.30 ± 30.712
SecondaryPlasma Concentration of Ruxolitinib at Weeks 4, 12, and 16

The concentration of ruxolitinib in the plasma was assessed.

Time frame:
pre-application at Weeks 4, 12, and 16
Reported as:
Mean · nanomolar
Plasma Concentration of Ruxolitinib at Weeks 4, 12, and 16
nanomolarRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVB
Week 418.7 ± 19.051.1 ± 45.4
Week 1223.3 ± 23.153.7 ± 55.0
Week 1649.3 ± 38.855.4 ± 43.9

Adverse events

Collected over up to approximately 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib 1.5% Cream BID0/20 (0%)2/20 (10%)9/20 (45%)
Ruxolitinib 1.5% Cream BID + NB-UVB0/35 (0%)0/35 (0%)15/35 (42.9%)
Total0/55 (0%)2/55 (3.6%)24/55 (43.6%)
Most frequent serious events
Most frequent serious events
EventRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVBTotal
Generalised tonic-clonic seizureNervous system disorders1/200/351/55
Intestinal obstructionGastrointestinal disorders1/200/351/55
Small intestinal perforationGastrointestinal disorders1/200/351/55
Most frequent other events
Showing 10 of 27
Most frequent other events
EventRuxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVBTotal
Application site acneGeneral disorders2/204/356/55
Procedural site reactionInjury, poisoning and procedural complications0/204/354/55
BronchitisInfections and infestations2/200/352/55
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/201/353/55
PyrexiaGeneral disorders2/200/352/55
Oral herpesInfections and infestations0/203/353/55
Upper respiratory tract infectionInfections and infestations1/203/354/55
Skin hyperpigmentationSkin and subcutaneous tissue disorders0/202/352/55
AcneSkin and subcutaneous tissue disorders1/201/352/55
Animal biteInjury, poisoning and procedural complications1/200/351/55

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ruxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVBTotal
Mean42.0 ± 18.9752.5 ± 14.2548.7 ± 16.75
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVBTotal
Female101727
Male101828
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ruxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVBTotal
Hispanic or Latino224
Not Hispanic or Latino183250
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib 1.5% Cream BIDRuxolitinib 1.5% Cream BID + NB-UVBTotal
White/Caucasian112536
Black/African-American123
Asian6612
American-Indian/Alaska Native202
East Indian011
Arab011
08

Study locations

13 sites
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • UC Davis Health
    Sacramento, California 95816, United States
  • Palo Alto Medical Foundation
    Sunnyvale, California 94086, United States
  • Delricht Clinical Research - Clinedge - Ppds Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Aesthetic and Dermatology Center
    Rockville, Maryland 20850, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01605, United States
  • Henry Ford Medical Center - New Center One
    Detroit, Michigan 48202, United States
  • Austin Institute For Clinical Research Aicr Pflugerville
    Pflugerville, Texas 78660, United States
  • Principle Research Solutions
    Spokane, Washington 99202, United States
  • Simcomed Health Ltd
    Barrie, Ontario L4M 7G1, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1X2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Dec 2023, 19 months.

Results were first posted in Feb 2025, 1 year 2 months after primary completion.

Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2022
First posted
Feb 21, 2022
StartActual
May 5, 2022
Primary completionActual
Dec 19, 2023
CompletionActual
Dec 19, 2023
Results first posted
Feb 20, 2025
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05247489
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
May 5, 2022
Primary completion
Dec 19, 2023
Completion
Dec 19, 2023
Results posted
Feb 20, 2025
Last update
Feb 20, 2025

Study contacts

Haq Nawaz, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion